Effect of menopause on the modified Rodnan skin score in systemic sclerosis

Arthritis Research and Therapy

Volumn 16, Issue 3, 2014, Pages

  Vinet, Évelyne ^a   Bernatsky, Sasha ^a   Hudson, Marie ^b,c   Pineau, Christian A ^a   Baron, Murray ^b   Pope, J ^d   Markland, J ^d   Robinson, D ^d   Jones, N ^d   Khalidi, N ^d   Larche M ^d   Docherty, P ^d   Kaminska, E ^d   LeClercq, S ^d   Masetto, A ^d   Sutton, E ^d   Mathieu, J P ^d   Ligier, S ^d   Grodzicky, T ^d   Gyger, G ^d   Thorne, C ^d   Smith, D ^d   Fortin, P R ^d   Fritzler, M ^e   more..

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Lady Davis Institute for Medical Research ^*

^e Advanced Diagnostics Laboratory   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; COHORT ANALYSIS; DISEASE DURATION; EXPOSURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MODIFIED RODNAN SKIN SCORE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHYSICAL EXAMINATION; POSTMENOPAUSE; SKINFOLD; SMOKING; SYSTEMIC SCLEROSIS; AGED; DRUG EFFECTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREMENOPAUSE; QUESTIONNAIRE; REGRESSION ANALYSIS; SCLERODERMA, SYSTEMIC; SKIN;

ANTIRHEUMATIC AGENT; CYCLOPHOSPHAMIDE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PREMENOPAUSE; QUESTIONNAIRES; REGRESSION ANALYSIS; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84902733970     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4587     Document Type: Article

References (22)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003. 10.1056/NEJMra0806188, 19420368.
2. Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 2009, 48:iii14-iii18.
3. Postlethwaite AE, Harris LJ, Raza SH, Kodura S, Akhigbe T. Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother 2010, 11:789-806. 10.1517/14656561003592177, 2837533, 20210685.
4. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24-week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996, 35:364-372. 10.1093/rheumatology/35.4.364, 8624641.
5. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001, 44:1351-1358. 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I, 11407694.
6. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666. 10.1056/NEJMoa055120, 16790698.
7. Martin F, Lauwerys B, Lefèbvre C, Devogelaer JP, Houssiau FA. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997, 6:254-257. 10.1177/096120339700600307, 9104732.
8. Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis. J Rheumatol 2008, 35:11-13.
9. Soldano S, Montagna P, Brizzolara R, Sulli A, Parodi A, Seriolo B, Paolino S, Villaggio B, Cutolo M. Effects of estrogens on extracellular matrix synthesis in cultures of human normal and scleroderma skin fibroblasts. Ann NY Acad Sci 2010, 1193:25-29. 10.1111/j.1749-6632.2009.05296.x, 20398004.
10. Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol 2005, 53:555-568. quiz 569-572, 10.1016/j.jaad.2004.08.039, 16198774.
11. Brincat M, Kabalan S, Studd JW, Moniz CF, de Trafford J, Montgomery J. A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman. Obstet Gynecol 1987, 70:840-845.
12. Maheux R, Naud F, Rioux M, Grenier R, Lemay A, Guy J, Langevin M. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994, 170:642-649. 10.1016/S0002-9378(94)70242-X, 8116726.
13. Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, Ohmann C, Gensch K, Ruzicka T. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 2010, 49:1336-1345. 10.1093/rheumatology/keq077, 20371505.
14. Giordano N, Puccetti L, Papakostas P, Di Pietra N, Bruni F, Pasqui AL, Acampa M, Bocchi V, Donati V, Voglino M, Fioravanti A, Montella A, Auteri A, Nuti R, Pastorelli M. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study. Int J Immunopathol Pharmacol 2010, 23:1185-1194.
15. Furst DE, Clements PJ, Steen VD, Medsger TA, Masi AT, D'Angelo WA, Lachenbruch PA, Grau RG, Seibold JR. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998, 25:84-88.
16. Kanda N, Watanabe S. Regulatory roles of sex hormones in cutaneous biology and immunology. J Dermatol Sci 2005, 38:1-7. 10.1016/j.jdermsci.2004.10.011, 15795118.
17. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
18. Hudson M, Suissa S. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010, 62:805-810. 10.1002/acr.20124, 20535791.
19. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FF, Weisman M, Barr W, Moreland L, Medsger TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally EV, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006, 65:1325-1329. 10.1136/ard.2005.050187, 1798331, 16540546.
20. Medsger TA. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003, 29:255-273. 10.1016/S0889-857X(03)00023-1, 12841294.
21. Hudson M, Lo E, Baron M, Steele R. Canadian Scleroderma Research Group. Modeling smoking in systemic sclerosis: a comparison of different statistical approaches. Arthritis Care Res (Hoboken) 2011, 63:570-578.
22. Colditz GA, Stampfer MJ, Willett WC, Stason WB, Rosner B, Hennekens CH, Speizer FE. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 1987, 126:319-325. 10.1093/aje/126.2.319, 3605058.